Uppsala, May 25, 2020. Gradientech is pleased to announce the appointment of three new members to the company’s board including a new board chair, effective from May 14, 2020. The new board members have been recruited to strengthen the company with internationally acquired key competences to prepare for the market launch of Gradientech’s in vitro diagnostic system for ultrarapid antibiotic susceptibility testing.
Gradientech AB (publ) interim report for Q1 2020 is now available in Swedish on the company’s website www.gradientech.se.
Gradientech AB (publ) delårsrapport för Q1 2020 är nu tillgänglig på bolagets hemsida www.gradientech.se.
Uppsala, April 30, 2020. Gradientech has closed a rights issue among its existing shareholders for a total of USD 2.1 million (SEK 21 million). The rights issue was oversubscribed with a subscription rate corresponding to 135 percent.
Gradientech AB (publ) announces today that the annual report for 2019 has been published and is available on the company’s website www.gradientech.se.
Gradientechs årsredovisning för 2019 har idag publicerats på bolagets hemsida.
Uppsala, March 27, 2020. Gradientech has been awarded with SEK 6.3M from the highly competitive BIO-X Accelerate program, to support the commercialization journey of its diagnostic system QuickMIC®. QuickMIC is an ultra-rapid system designed to provide fast and targeted treatment for sepsis patients.
Uppsala, February 26, 2020. Gradientech today announces the scientific publication of a navel multiplex fluidic chip for rapid antibiotic susceptibility testing (ASn. The chip can generate AST results within 2-4 ho urs, which is at least 20 hours faster than current AST methods used in hospital laboratories.
Gradientech AB (publ) year-end report for 2019 is now available in Swedish on the company’s website www.gradientech.se.
Gradientech AB:s (publ) bokslutskommuniké för 2019 finns nu tillgänglig på bolagets hemsida www.gradientech.se.